NASDAQ:GNMX - Aevi Genomic Medicine Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.65 +0.05 (+3.13 %)
(As of 05/28/2018 01:26 AM ET)
Previous Close$1.65
Today's Range$1.62 - $1.69
52-Week Range$0.98 - $2.65
Volume57,626 shs
Average Volume70,227 shs
Market Capitalization$97.91 million
P/E RatioN/A
Dividend YieldN/A
Beta1.1

About Aevi Genomic Medicine (NASDAQ:GNMX)

Aevi Genomic Medicine logoAevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Receive GNMX News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GNMX
CUSIPN/A
Phone610-254-4201

Debt

Debt-to-Equity RatioN/A
Current Ratio5.78
Quick Ratio5.78

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.38 per share
Price / Book4.34

Profitability

EPS (Most Recent Fiscal Year)($0.83)
Net Income$-34,710,000.00
Net MarginsN/A
Return on Equity-160.09%
Return on Assets-127.64%

Miscellaneous

Employees17
Outstanding Shares59,340,000

Aevi Genomic Medicine (NASDAQ:GNMX) Frequently Asked Questions

What is Aevi Genomic Medicine's stock symbol?

Aevi Genomic Medicine trades on the NASDAQ under the ticker symbol "GNMX."

How were Aevi Genomic Medicine's earnings last quarter?

Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) posted its quarterly earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.01. View Aevi Genomic Medicine's Earnings History.

What price target have analysts set for GNMX?

2 analysts have issued 12 month price objectives for Aevi Genomic Medicine's shares. Their predictions range from $1.50 to $7.00. On average, they anticipate Aevi Genomic Medicine's share price to reach $4.25 in the next year. View Analyst Ratings for Aevi Genomic Medicine.

Who are some of Aevi Genomic Medicine's key competitors?

Who are Aevi Genomic Medicine's key executives?

Aevi Genomic Medicine's management team includes the folowing people:
  • Mr. Michael F. Cola, Chief Exec. Officer, Pres and Director (Age 58)
  • Mr. Brian D. Piper MBA, CFO & Corp. Sec. (Age 46)
  • Dr. Garry A. Neil, Chief Scientific Officer (Age 64)
  • Dr. Nir Shapir Ph.D., Sr. VP of R&D
  • Dr. David A. Fitts M.P.H., Ph.D., Head of Statistical Sciences & Data Management and VP

Has Aevi Genomic Medicine been receiving favorable news coverage?

Media headlines about GNMX stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aevi Genomic Medicine earned a daily sentiment score of 0.11 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 46.00 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Aevi Genomic Medicine's major shareholders?

Aevi Genomic Medicine's stock is owned by a number of of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (0.17%). Company insiders that own Aevi Genomic Medicine stock include Garry Arthur Neil, Michael F Cola, Philip R Harper and Sol J Barer. View Institutional Ownership Trends for Aevi Genomic Medicine.

Which institutional investors are buying Aevi Genomic Medicine stock?

GNMX stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. Company insiders that have bought Aevi Genomic Medicine stock in the last two years include Garry Arthur Neil, Michael F Cola, Philip R Harper and Sol J Barer. View Insider Buying and Selling for Aevi Genomic Medicine.

How do I buy shares of Aevi Genomic Medicine?

Shares of GNMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aevi Genomic Medicine's stock price today?

One share of GNMX stock can currently be purchased for approximately $1.65.

How big of a company is Aevi Genomic Medicine?

Aevi Genomic Medicine has a market capitalization of $97.91 million. The biotechnology company earns $-34,710,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Aevi Genomic Medicine employs 17 workers across the globe.

How can I contact Aevi Genomic Medicine?

Aevi Genomic Medicine's mailing address is 435 DEVON PARK DRIVE SUITE 715, WAYNE PA, 19087. The biotechnology company can be reached via phone at 610-254-4201 or via email at [email protected]


MarketBeat Community Rating for Aevi Genomic Medicine (GNMX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  98 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  208
MarketBeat's community ratings are surveys of what our community members think about Aevi Genomic Medicine and other stocks. Vote "Outperform" if you believe GNMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aevi Genomic Medicine (NASDAQ:GNMX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Aevi Genomic Medicine in the last 12 months. Their average twelve-month price target is $4.25, suggesting that the stock has a possible upside of 157.58%. The high price target for GNMX is $7.00 and the low price target for GNMX is $1.50. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.672.672.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.25$4.25$4.25$7.50
Price Target Upside: 157.58% upside235.65% upside235.65% upside492.32% upside

Aevi Genomic Medicine (NASDAQ:GNMX) Consensus Price Target History

Price Target History for Aevi Genomic Medicine (NASDAQ:GNMX)

Aevi Genomic Medicine (NASDAQ:GNMX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/28/2017Jefferies GroupReiterated RatingHold$1.50LowView Rating Details
8/16/2017Needham & Company LLCLower Price TargetBuy ➝ Buy$9.00 ➝ $7.00MediumView Rating Details
5/10/2017UBSReiterated RatingPositiveN/AView Rating Details
12/6/2016HC WainwrightInitiated CoverageBuy$14.00N/AView Rating Details
11/4/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
(Data available from 5/28/2016 forward)

Earnings

Aevi Genomic Medicine (NASDAQ:GNMX) Earnings History and Estimates Chart

Earnings by Quarter for Aevi Genomic Medicine (NASDAQ:GNMX)

Aevi Genomic Medicine (NASDAQ:GNMX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.15)($0.14)($0.15)
Q2 20182($0.15)($0.15)($0.15)
Q3 20182($0.16)($0.15)($0.16)
Q4 20182($0.15)($0.14)($0.15)

Aevi Genomic Medicine (NASDAQ GNMX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2018Q1 2018($0.14)($0.15)ViewN/AView Earnings Details
3/13/2018Q4 2017($0.15)($0.13)ViewN/AView Earnings Details
11/2/2017Q3 2017($0.24)($0.23)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.26)($0.22)ViewListenView Earnings Details
5/10/2017Q1 2017($0.27)($0.29)ViewN/AView Earnings Details
3/9/2017Y 2016($0.31)($0.22)ViewN/AView Earnings Details
11/3/2016Q316($0.30)($0.29)ViewN/AView Earnings Details
8/4/2016Q2($0.30)($0.69)ViewN/AView Earnings Details
5/10/2016Q1 2016($0.29)($0.34)ViewN/AView Earnings Details
2/17/2016Q4 2015($0.27)($0.25)ViewN/AView Earnings Details
10/22/2015Q3 2015($0.31)($0.33)ViewN/AView Earnings Details
8/10/2015Q2 2015($0.34)($0.28)ViewN/AView Earnings Details
4/17/2015Q1 2015($0.34)($0.36)ViewN/AView Earnings Details
2/13/2015Q4 2014($0.22)($0.30)ViewN/AView Earnings Details
10/15/2014Q3 2014($0.25)($0.21)ViewN/AView Earnings Details
7/16/2014Q2 2014($0.23)($0.21)ViewN/AView Earnings Details
5/8/2014Q1 2014($0.28)ViewN/AView Earnings Details
2/20/2014Q4 2013($0.38)ViewN/AView Earnings Details
11/7/2013Q3 2013($0.25)ViewN/AView Earnings Details
8/6/2013Q2 2013($0.11)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.25)($0.29)ViewN/AView Earnings Details
3/14/2013Q4 2012($0.27)($0.17)ViewN/AView Earnings Details
11/14/2012Q3 2012($0.25)ViewN/AView Earnings Details
8/13/2012Q2 2012($0.69)ViewN/AView Earnings Details
5/14/2012Q1 2012($0.28)ViewN/AView Earnings Details
3/6/2012Q4 2011($0.61)ViewN/AView Earnings Details
11/10/2011Q3 2011($0.36)ViewN/AView Earnings Details
8/12/2011Q2 2011($0.26)ViewN/AView Earnings Details
5/12/2011Q1 2011($0.06)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Aevi Genomic Medicine (NASDAQ:GNMX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Aevi Genomic Medicine (NASDAQ GNMX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.70%
Institutional Ownership Percentage: 22.83%
Insider Trading History for Aevi Genomic Medicine (NASDAQ:GNMX)
Institutional Ownership by Quarter for Aevi Genomic Medicine (NASDAQ:GNMX)

Aevi Genomic Medicine (NASDAQ GNMX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/17/2017Garry Arthur NeilInsiderBuy75,000$1.26$94,500.00114,774View SEC Filing  
10/17/2017Michael F ColaCEOBuy119,047$1.26$149,999.22218,483View SEC Filing  
10/17/2017Sol J BarerDirectorBuy421,032$1.26$530,500.321,028,032View SEC Filing  
8/23/2017Philip R HarperMajor ShareholderBuy10,361$1.20$12,433.204,870,344View SEC Filing  
8/10/2017Philip R HarperMajor ShareholderBuy20,470$1.19$24,359.304,865,683View SEC Filing  
4/28/2017Sol J BarerDirectorBuy100,000$1.57$157,000.00607,000View SEC Filing  
4/26/2017Sol J BarerDirectorBuy100,000$1.54$154,000.00507,000View SEC Filing  
3/24/2017Philip R HarperMajor ShareholderBuy1,058,531$1.78$1,884,185.184,786,682View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aevi Genomic Medicine (NASDAQ GNMX) News Headlines

Source:
DateHeadline
Aevi Genomic Medicine (GNMX) versus ADMA Biologics (ADMA) Head-To-Head AnalysisAevi Genomic Medicine (GNMX) versus ADMA Biologics (ADMA) Head-To-Head Analysis
www.americanbankingnews.com - May 25 at 11:14 PM
Curis (CRIS) and Aevi Genomic Medicine (GNMX) Head-To-Head ReviewCuris (CRIS) and Aevi Genomic Medicine (GNMX) Head-To-Head Review
www.americanbankingnews.com - May 24 at 5:17 AM
Wired News - uniQure Announced Presentation of Preclinical Data Demonstrating Advances in Distribution of Gene Therapy at ASGCT Annual Meeting in ChicagoWired News - uniQure Announced Presentation of Preclinical Data Demonstrating Advances in Distribution of Gene Therapy at ASGCT Annual Meeting in Chicago
finance.yahoo.com - May 22 at 8:23 AM
Aevi Genomic Medicine: Try Subgroups Until It Works?Aevi Genomic Medicine: Try Subgroups Until It Works?
seekingalpha.com - May 20 at 5:50 PM
 Aevi Genomic Medicine, Inc. (GNMX) Given $5.00 Consensus Price Target by Analysts Aevi Genomic Medicine, Inc. (GNMX) Given $5.00 Consensus Price Target by Analysts
www.americanbankingnews.com - May 18 at 11:47 AM
Aevi Genomic Medicine, Inc. to Post Q2 2018 Earnings of ($0.15) Per Share, Jefferies Group Forecasts (GNMX)Aevi Genomic Medicine, Inc. to Post Q2 2018 Earnings of ($0.15) Per Share, Jefferies Group Forecasts (GNMX)
www.americanbankingnews.com - May 18 at 7:30 AM
Aevi Genomic Medicine (GNMX) Issues  Earnings Results, Misses Expectations By $0.01 EPSAevi Genomic Medicine (GNMX) Issues Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 16 at 10:35 AM
Aevi Genomic Medicine: 1Q Earnings SnapshotAevi Genomic Medicine: 1Q Earnings Snapshot
finance.yahoo.com - May 15 at 5:45 PM
Aevi Genomic Medicine Reports First Quarter 2018 Financial Results and Provides Business UpdateAevi Genomic Medicine Reports First Quarter 2018 Financial Results and Provides Business Update
finance.yahoo.com - May 15 at 8:36 AM
Zacks: Analysts Expect Aevi Genomic Medicine, Inc. (GNMX) to Announce -$0.15 EPSZacks: Analysts Expect Aevi Genomic Medicine, Inc. (GNMX) to Announce -$0.15 EPS
www.americanbankingnews.com - May 12 at 11:24 AM
What Are Analysts Expecting From Aevi Genomic Medicine Inc (NASDAQ:GNMX) Over The Next Few Years?What Are Analysts Expecting From Aevi Genomic Medicine Inc (NASDAQ:GNMX) Over The Next Few Years?
finance.yahoo.com - May 8 at 5:32 PM
Aevi Genomic Medicine (GNMX) Lifted to Sell at ValuEngineAevi Genomic Medicine (GNMX) Lifted to Sell at ValuEngine
www.americanbankingnews.com - May 3 at 5:12 PM
Analysts Expect Aevi Genomic Medicine, Inc. (GNMX) to Post ($0.15) EPSAnalysts Expect Aevi Genomic Medicine, Inc. (GNMX) to Post ($0.15) EPS
www.americanbankingnews.com - May 2 at 11:19 PM
Aevi Genomic Medicine (GNMX) Set to Announce Quarterly Earnings on TuesdayAevi Genomic Medicine (GNMX) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 11:10 AM
Form DEF 14A Sage Therapeutics, Inc. For: Jun 06Form DEF 14A Sage Therapeutics, Inc. For: Jun 06
www.streetinsider.com - April 30 at 5:10 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of ...SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of ...
www.businesswire.com - April 30 at 5:10 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Aevi Genomic Medicine, Inc. -- GNMXSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Aevi Genomic Medicine, Inc. -- GNMX
finance.yahoo.com - April 30 at 5:10 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Aevi Genomic Medicine, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Aevi Genomic Medicine, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
www.prnewswire.com - April 29 at 8:54 PM
Zacks: Brokerages Expect Aevi Genomic Medicine, Inc. (GNMX) to Announce -$0.15 EPSZacks: Brokerages Expect Aevi Genomic Medicine, Inc. (GNMX) to Announce -$0.15 EPS
www.americanbankingnews.com - April 24 at 11:18 PM
Zacks: Analysts Set $5.00 Target Price for Medgenics Inc (GNMX)Zacks: Analysts Set $5.00 Target Price for Medgenics Inc (GNMX)
www.americanbankingnews.com - April 17 at 1:32 AM
Head-To-Head Contrast: Medgenics (GNMX) & Momenta Pharmaceuticals (MNTA)Head-To-Head Contrast: Medgenics (GNMX) & Momenta Pharmaceuticals (MNTA)
www.americanbankingnews.com - April 13 at 9:21 PM
Medgenics Inc (GNMX) Expected to Post Earnings of -$0.15 Per ShareMedgenics Inc (GNMX) Expected to Post Earnings of -$0.15 Per Share
www.americanbankingnews.com - April 8 at 1:17 AM
Investor Expectations to Drive Momentum within Brooks Automation, Broadridge Financial Solutions, Vivint Solar, Northwest Natural Gas, Aevi Genomic Medicine, and Northern Oil and Gas — Discovering Underlying Factors of InfluenceInvestor Expectations to Drive Momentum within Brooks Automation, Broadridge Financial Solutions, Vivint Solar, Northwest Natural Gas, Aevi Genomic Medicine, and Northern Oil and Gas — Discovering Underlying Factors of Influence
finance.yahoo.com - April 6 at 8:35 AM
Brokerages Anticipate Medgenics Inc (GNMX) to Announce ($0.15) Earnings Per ShareBrokerages Anticipate Medgenics Inc (GNMX) to Announce ($0.15) Earnings Per Share
www.americanbankingnews.com - April 2 at 9:16 PM
 Analysts Set $5.00 Target Price for Medgenics Inc (GNMX) Analysts Set $5.00 Target Price for Medgenics Inc (GNMX)
www.americanbankingnews.com - March 30 at 1:21 PM
Medgenics Inc (GNMX) Expected to Earn Q1 2018 Earnings of ($0.14) Per ShareMedgenics Inc (GNMX) Expected to Earn Q1 2018 Earnings of ($0.14) Per Share
www.americanbankingnews.com - March 26 at 1:04 AM
GNMX: Q4 2017 Results / Operational UpdateGNMX: Q4 2017 Results / Operational Update
finance.yahoo.com - March 22 at 5:31 PM
GNMX: ASCEND Timeline On-Track, Topline ~Mid-2018. Additional Pipeline ExpansionGNMX: ASCEND Timeline On-Track, Topline ~Mid-2018. Additional Pipeline Expansion
finance.yahoo.com - March 22 at 5:31 PM
 Brokerages Anticipate Medgenics Inc (GNMX) to Post -$0.15 Earnings Per Share Brokerages Anticipate Medgenics Inc (GNMX) to Post -$0.15 Earnings Per Share
www.americanbankingnews.com - March 22 at 1:18 AM
Aevi Genomic Medicine to Present at the 17th Annual Needham Healthcare ConferenceAevi Genomic Medicine to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 20 at 8:36 AM
 Brokerages Set $5.33 Price Target for Medgenics Inc (GNMX) Brokerages Set $5.33 Price Target for Medgenics Inc (GNMX)
www.americanbankingnews.com - March 16 at 3:18 PM
FY2019 EPS Estimates for Medgenics Inc (GNMX) Cut by AnalystFY2019 EPS Estimates for Medgenics Inc (GNMX) Cut by Analyst
www.americanbankingnews.com - March 16 at 2:20 PM
Medgenics Inc Expected to Earn Q1 2018 Earnings of ($0.15) Per Share (GNMX)Medgenics Inc Expected to Earn Q1 2018 Earnings of ($0.15) Per Share (GNMX)
www.americanbankingnews.com - March 15 at 7:57 AM
Aevi Genomic Medicine, Inc. to Host Earnings CallAevi Genomic Medicine, Inc. to Host Earnings Call
finance.yahoo.com - March 13 at 8:33 AM
Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateAevi Genomic Medicine Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 13 at 8:33 AM
Head-To-Head Survey: Anavex Life Sciences (AVXL) & Medgenics (GNMX)Head-To-Head Survey: Anavex Life Sciences (AVXL) & Medgenics (GNMX)
www.americanbankingnews.com - March 12 at 11:27 AM
Aevi expands drug development deal with Japanese biopharm firmAevi expands drug development deal with Japanese biopharm firm
finance.yahoo.com - March 7 at 6:28 PM
Aevi Genomic Medicine Expands Collaboration with Kyowa Hakko KirinAevi Genomic Medicine Expands Collaboration with Kyowa Hakko Kirin
finance.yahoo.com - March 7 at 8:25 AM
Aevi Genomic Medicine to Host Conference Call to Announce Fourth Quarter and Year End 2017 Financial ResultsAevi Genomic Medicine to Host Conference Call to Announce Fourth Quarter and Year End 2017 Financial Results
finance.yahoo.com - March 6 at 8:22 AM
-$0.15 EPS Expected for Medgenics Inc (GNMX) This Quarter-$0.15 EPS Expected for Medgenics Inc (GNMX) This Quarter
www.americanbankingnews.com - March 4 at 9:14 PM
 Analysts Set $5.25 Price Target for Medgenics Inc (GNMX) Analysts Set $5.25 Price Target for Medgenics Inc (GNMX)
www.americanbankingnews.com - February 18 at 11:12 PM
Zacks: Brokerages Expect Medgenics Inc (GNMX) Will Post Earnings of -$0.17 Per ShareZacks: Brokerages Expect Medgenics Inc (GNMX) Will Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - February 16 at 5:18 AM
FY2018 EPS Estimates for Medgenics Inc (GNMX) Increased by AnalystFY2018 EPS Estimates for Medgenics Inc (GNMX) Increased by Analyst
www.americanbankingnews.com - February 15 at 11:20 AM
FY2022 Earnings Forecast for Medgenics Inc Issued By Jefferies Group (GNMX)FY2022 Earnings Forecast for Medgenics Inc Issued By Jefferies Group (GNMX)
www.americanbankingnews.com - February 14 at 4:12 PM
Comparing Medgenics (GNMX) & Trillium Therapeutics (TRIL)Comparing Medgenics (GNMX) & Trillium Therapeutics (TRIL)
www.americanbankingnews.com - February 1 at 12:01 PM
 Analysts Set $5.17 Price Target for Medgenics Inc (GNMX) Analysts Set $5.17 Price Target for Medgenics Inc (GNMX)
www.americanbankingnews.com - January 31 at 7:14 PM
Zacks: Analysts Anticipate Medgenics Inc (GNMX) to Announce -$0.17 EPSZacks: Analysts Anticipate Medgenics Inc (GNMX) to Announce -$0.17 EPS
www.americanbankingnews.com - January 30 at 5:08 AM
Zacks: Medgenics Inc (GNMX) Given $5.17 Consensus Price Target by AnalystsZacks: Medgenics Inc (GNMX) Given $5.17 Consensus Price Target by Analysts
www.americanbankingnews.com - January 23 at 11:10 PM
Contrasting Mateon Therapeutics (MATN) & Aevi Genomic Medicine (GNMX)Contrasting Mateon Therapeutics (MATN) & Aevi Genomic Medicine (GNMX)
www.americanbankingnews.com - January 15 at 11:40 AM
Aevi Genomic Medicine, Inc. (GNMX) Expected to Post Earnings of -$0.17 Per ShareAevi Genomic Medicine, Inc. (GNMX) Expected to Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - January 13 at 7:52 AM

SEC Filings

Aevi Genomic Medicine (NASDAQ:GNMX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aevi Genomic Medicine (NASDAQ:GNMX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aevi Genomic Medicine (NASDAQ GNMX) Stock Chart for Monday, May, 28, 2018

Loading chart…

This page was last updated on 5/28/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.